Jon DeVries Appointed as CEO of Mirada Medical

Jon DeVries Appointed as CEO of Mirada Medical

Healthcare Tech Outlook | Thursday, September 30, 2021

Jon DeVries joins Mirada as the CEO, and he will help the firm strengthen its position as a leader in oncology treatment.

FREMONT, CA: Jon DeVries, a seasoned business leader, has been named CEO of Mirada Medical. DeVries is a well-known tech visionary who is most recognized for increasing artificial intelligence (AI) usage in healthcare and commercializing medical imaging products. Growing Merge Healthcare's clinical trials and enterprise imaging businesses, as well as developing Qlarity Imaging's QuantX, the first FDA-cleared diagnostic AI software used to analyze breast cancer as a cloud-based SaaS solution, are among his accomplishments. In addition, he founded IBM Watson Health Imaging's first AI service.

DeVries will be situated in Chicago, strengthening Mirada's current US presence, including a large customer base and robust support infrastructure. He will be in charge of the international management team, which will be responsible for accelerating the US and international expansion. DeVries plans to accomplish this by delivering a full suite of cutting-edge oncology treatment guiding products and expanding on a partner base that already includes GE Health, Boston Scientific, and Philips.

DeVries joins Mirada to help the firm strengthen its position as a leader in oncology treatment guiding, a vital area of cancer treatment that is seeing fast market growth and clinical adoption. Mirada's globally recognized quantitative image analysis and illness characterization expertise will be accelerated under DeVries' leadership. Mirada will lead the next generation of world-class diagnostic imaging technologies, combining his commercial experience and the company's strong research team. This will make a significant impact on cancer patients' and their treatment teams' lives.

Mirada has earned a lot of attention for bringing cutting-edge AI technologies to the front lines of cancer treatment. It is the only firm in the world to offer FDA-cleared and clinically approved AI technology for highlighting organs being scanned for radiation treatment planning. The NHS in the United Kingdom recently awarded Mirada two funds as part of the NHS AI in Health and Care Awards to help the company continue to improve its solutions. The company now has tens of thousands of clinics around the world.

Weekly Brief